Latest Industry Insights

Up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.

Scripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr. Colette Saccomanno to learn more.

At a recent London Proteomics Discussion Group Meeting, Professor Roman Fischer kicked off the event by addressing the apparent "failure" of proteomics to deliver new clinical biomarkers thus far. Technology Networks sat down with Fischer to discuss spatial proteomics, and to expand on some of the key aspects of his research.

Codexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.

Our immune system is incredibly complex. Developing a complete understanding is an enormous undertaking but one to which scientists have been striving in order to advance disease understanding and improve treatments.

Technology Networks spoke with James Graham, Executive Director at Recce Pharmaceuticals, to learn more about how synthetic antibiotics differ from those derived from natural sources. He also discusses how the company has developed a novel class of synthetic antibiotics and elaborates on their mechanism of action.

Lab-based informatics systems, such as LIMS and ELNs, are becoming more commonly used in labs. We spoke with Jeff Carter, co-founder and COO of lab software company Arxspan, to discover how COVID-19 has helped drive digitization and how tools are developing to become more flexible and connected.

Technology Networks recently spoke with David Younger, PhD, Co-founder and CEO of A-Alpha Bio, to learn more about how the company has harnessed synthetic biology and next-generation sequencing techniques to measure millions of interactions between proteins in a single test tube. This enables the identification of potential drugs for the treatment of infectious diseases, including COVID-19.

One of the COVID-19 vaccine candidates that received fast track designation by the FDA is mRNA-1273, developed by Moderna, a clinical stage biotechnology company. The company has shared the positive interim results from a Phase I clinical trial of the vaccine in The New England Journal of Medicine .

Technology Networks spoke with Rohan Thakur, Executive Vice President of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the company's latest analytical technologies and their capabilities.